Blog / Archives
Global “Risk-On” Rally Across Most Sectors Especially Biotechnology
The Bi-Partisan Cliff Deal Nobody Likes (Except the Market) Investors like the tax deal as it is favorable to investors despite the tax increases. Stocks are holding their gains after a...
Rayno Biopharmaceutical Focus Stocks YTD: Top Performers include AMRI,GILD, REGN
Outstanding Year for Biotechnology -Average Performance is up 35% YTD Many Rayno Life Science Stocks have outperformed the sector and the ETFs: Albany Molecular Inc. (AMRI), a contract research...
Life Science Stocks Brought Down by Dysfunctional Congress
End of Year Rally Crushed By Turmoil in Budget Talks Up until late yesterday investors were optimistic about a budget deal with the "Kubuki Theater" Congress. You have heard enough about the fiscal...
Rayno Life Sciences Stocks To Watch: ALR, CPHD, QDEL, RGDX- Update 1
Rayno Tools and Diagnostics Stocks Continue Rally Tools and Diagnostic stocks have been the laggards in the Rayno Life Sciences Portfolio compared to biopharmaceutical stocks. Selected stocks within...
Another Stealth Rally In Biopharmaceuticals: AMGN IBB REGN VPHM
Rayno Life Science Stocks Move Higher Biotech stocks are ignoring the volatility from the political fray today with big moves in many Rayno Life Science stocks and a 1.5% move in the bellwether ETF...
Rayno DX and Tools: Update on metrics and performance
Pure Play Clinical Diagnostic Companies Here is data on our clinical diagnostics universe including Q3 revenues and earnings. New buy is Cepheid (CPHD) under $32. Sequenom is up 22% over 5 days...
Rayno Life Science Mid-day Movers: AMRI, ASTX, CPHD, ILMN, REGN
Markets Are Back To Fretting About Fiscal Cliff Bernanke scolded Congress on the fiscal cliff and markets turned down. Despite a lackluster market down about 0.3% there is a lot of green in biotech....
Stocks Turn Green in Major Reversal: Biotechs In Stealth Rally
Politicians Offer Hope Of Deal and Are Looking For Common Ground Boehner puts revenue on the table passing off next move to DEMS for cuts. Reid says he will not wait till end of the year to cut a...
Update On Emerging Biomarker Diagnostics: BG Medicine, Response Genetics, Vermillion
Response Genetics (RGDX) Offers Good Value and Is Positioned For Revenue Growth In April we compared two emerging companies focused in biomarker diagnostics, BG Medicine, Inc. and Vermillion, Inc....
Raygent Biopharmaceutical Portfolio: Celgene (CELG) and Gilead (GILD) Ignite Rally
A languishing biotech sector rallied today with clinical news with Hepatitis C (HCV) drugs. The Rayno Biopharma Portfolio was up 2.4% led by Gilead Sciences (GILD) up 11.5%, Regeneron (REGN) up 3.3%...